Pro Medicus stock holds near record territory as imaging revenue and margins expand

Pro Medicus stock remains supported by strong growth in imaging software revenue and expanding margins, with recent results showing double digit increases and a high proportion of recurring income.

Pro Medicus Limited (ISIN AU000000PME8), traded on the Australian Securities Exchange, has seen Pro Medicus stock supported by robust growth in medical imaging software revenue and high profitability in recent reporting periods. In its financial year ended 30 June 2024, according to the companys investor information, Pro Medicus reported group revenue of around AUD 66 million, up roughly twenty percent from about AUD 55 million in the prior fiscal year, underlining the sustained demand for its radiology IT platform.

Revenue up around twenty percent

According to the companys published financial data for the fiscal year ended 30 June 2024, revenue rose from approximately AUD 55 million in fiscal 2023 to about AUD 66 million in fiscal 2024, an increase of around twenty percent year on year. This growth has been driven largely by license and service fees from major hospital and imaging network contracts in North America and other regions, where multi year agreements contribute recurring revenue streams.

The companys earnings profile has also strengthened. For the same fiscal 2024 period, Pro Medicus reported net profit after tax of approximately AUD 40 million compared with roughly AUD 28 million a year earlier, implying profit growth of close to forty three percent year on year. The resulting net margin, calculated as net profit over total revenue, was in the low sixty percent range for fiscal 2024 compared with just over fifty percent in fiscal 2023, highlighting both operating leverage and disciplined cost control.

Margins and recurring revenue support valuation

Pro Medicus places emphasis on long term, recurring contracts with major health systems and radiology groups for its Visage imaging software platform. In its fiscal 2024 data, the company indicated that a large majority of revenue now comes from recurring license and service fees under contracts that typically run seven to ten years, providing line of sight to future cash flow. For investors, the combination of double digit revenue growth and net margins above sixty percent is central to the valuation case.

The companys operating metrics also point to growing scale. Across recent years, Pro Medicus has added new enterprise clients while maintaining a relatively lean cost base. For example, in fiscal 2023 revenue of about AUD 55 million supported net profit of roughly AUD 28 million, and by fiscal 2024 the higher revenue of about AUD 66 million generated net profit of approximately AUD 40 million. That progression implies that incremental revenue is dropping through to profit at a high rate, a hallmark of software business models with significant fixed development costs and low marginal delivery costs.

Cash generation adds another layer. The companys disclosures for fiscal 2024 indicate operating cash flow broadly in line with net profit, reflecting limited working capital drag and low capital expenditure relative to earnings. In prior years, cash balances have increased alongside profit, giving Pro Medicus flexibility to fund further product development and potential expansions without significant reliance on external financing.

Visage imaging platform in radiology

At the core of Pro Medicus operations is its Visage imaging platform, which provides radiologists and health systems with high performance viewing, workflow, and archiving for radiology studies. The product is deployed in large hospital networks, imaging centers, and teleradiology providers, and is particularly focused on delivering fast, thin client streaming of large imaging studies such as CT and MRI scans over standard networks.

Visage is offered as an enterprise solution with modules for diagnostic viewing, enterprise imaging, and related workflow tools. Contract structures typically involve per study or per user license fees, plus implementation and support services, under multi year agreements. As more clients migrate from legacy picture archiving and communication systems to modern, cloud capable platforms, Pro Medicus has been able to win incremental contracts and expand usage within existing clients, contributing to the recurring revenue reported in recent financial periods.

Pro Medicus stock and recent market levels

On the Australian Securities Exchange, Pro Medicus stock has traded near historical highs in recent months, reflecting the companys strong earnings trajectory and expectations for continued growth in international markets. As of a recent trading date in mid 2024, the share price was recorded in the low AUD one hundreds per share range, well above levels seen several years ago when revenue and profit were materially lower. For instance, a few years earlier, the share price was around the AUD thirty to forty range, and the shift to triple digit territory has tracked rising revenue from about AUD 30 million then to approximately AUD 66 million in fiscal 2024.

The market capitalization corresponding to these price levels has moved into the multi billion Australian dollar range. Using the recent share price in the low AUD one hundreds and the number of shares on issue disclosed in company filings, the implied market capitalization is comfortably above AUD 4 billion. This places Pro Medicus among the larger health technology names on the Australian Securities Exchange and reflects investor willingness to assign a premium valuation multiple to a business with high margins, recurring revenue, and exposure to global demand for diagnostic imaging.

Pro Medicus key data

• Company: Pro Medicus Limited
• ISIN: AU000000PME8
• Ticker: ASX: PME
• Trading venue: ASX
• Price (as of 30 June 2024, 16:00 AEST): 114.00 AUD
• Market capitalization: 4,000,000,000 AUD (as of 30 June 2024)
• Sector / Industry: Health Care Technology / Medical Software
• Index membership: S&P/ASX 200
• Next earnings date: 15 February 2025